Enterome to Present Data on EO2401 in Adrenal Tumors at the European Society for Medical Oncology (ESMO) 2023 Congress
Read more
11
July 2023
Enterome announces first patient dosed in Phase 2 trial with OncoMimics™ immunotherapy EO2040 in Colorectal Cancer with ctDNA-defined Minimal Residual Disease
Read more
30
June 2023
Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer
Read more
16
June 2023
Enterome selected for the prestigious French Tech 2030 program designed to champion breakthrough technological innovations in France
Read more
14
June 2023
Enterome’s new OncoMimics™ immunotherapy, EO2463, demonstrates early efficacy and favorable safety in Phase 1/2 trial for indolent non-Hodgkin lymphoma
Read more
31
May 2023
Enterome announces sustained positive clinical outcomes with EO2401, its lead OncoMimics™ immunotherapy, in combination therapy in Glioblastoma at ASCO
Read more
09
May 2023
Enterome forms Scientific Advisory Board and Medical Advisory Group as it advances its OncoMimics™ immunotherapy pipeline for solid and liquid tumors
Read more
10
March 2023
Enterome’s Management to Attend Upcoming Meetings
Read more
12
December 2022
Enterome completes patient enrollment of Phase 2 ROSALIE study evaluating its lead immunotherapy, EO2401, in recurrent glioblastoma
